Nitrase Therapeutics
Jackson
About Nitrase Therapeutics
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $45.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2021)
- Website: nitrasetx.com
- Phone: 4153101058
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nitrase-therapeutics-69756 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.